News

Tumor types were selected based on clinical observations in the phase 1 study and a detailed analysis of potential patient stratification biomarkers across tumor indications. The study will

The two programs, which issue from Affinium’s FabI discovery platform acquired by Debiopharm in February 2014, will lead to the development of narrow-spectrum antibiotics. As part of the

The trial is designed to further add to the clinical experience to date by showing the safety and tolerability of ZS-9 and its ability to restore and maintain

As part of the deal, PanAm seeks to distribute a minimum of 5,000 ‘cartons’ per month, or 150,000 pills per month, for the balance of the year with

Insys manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD at its FDA-inspected and Drug Enforcement Administration (DEA) approved facility in Round Rock, Texas. Recently, Insys submitted a drug master

As part of the deal, Sorrento will receive research fees, up-front payment, milestone payments and royalties on future net sales. Following successful attainment of key milestones, Sorrento is

Roclatan achieved its primary efficacy endpoint of statistically significant superiority over each of its components on day 29. The Phase 2b 28-day clinical trial included 297 patients. The

The results from a randomized, non-inferiority, multicenter, comparative trial (N=758) establish that, despite a 29 % lower dose, Zubsolv provides equivalent efficacy compared to Suboxone film in patients

ALLOB is the first ever allogeneic differentiated osteoblastic cell therapy product developed for the treatment of orthopaedic conditions. Allogeneic cell therapy involves the harvesting of cells from a